I 
117TH CONGRESS 
1ST SESSION H. R. 1185 
To amend the Public Health Service Act to authorize grants to certain 
States to inform patients about the risks of opioids and their analogues, 
and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
FEBRUARY 18, 2021 
Mr. TRONE (for himself, Mr. RESCHENTHALER, Ms. LEGER FERNANDEZ, and 
Mr. MCKINLEY) introduced the following bill; which was referred to the 
Committee on Energy and Commerce 
A BILL 
To amend the Public Health Service Act to authorize grants 
to certain States to inform patients about the risks of 
opioids and their analogues, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Opioid Patients’ Right 
to Know Act of 2021’’. 
VerDate Sep 11 2014 
19:43 Mar 13, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1185.IH
H1185
pamtmann on DSKBC07HB2PROD with BILLS
SEC. 2. GRANT PROGRAM TO INFORM PATIENTS ABOUT 
THE RISKS OF OPIOIDS AND THEIR ANA-
LOGUES. 
Part J of title III of the Public Health Service Act 
(42 U.S.C. 280b et seq.) is amended by inserting after 
section 392A (42 U.S.C. 280b–1) the following: 
‘‘SEC. 392B. GRANT PROGRAM TO INFORM PATIENTS ABOUT 
THE RISKS OF OPIOIDS AND THEIR ANA-
LOGUES. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Director of the Centers for Disease Control and Pre-
vention, shall award one grant (over the life of the pro-
gram under this section) to each eligible State to inform 
covered health care providers about— 
‘‘(1) the requirement of the State described in 
subsection (b); and 
‘‘(2) recommendations for safe opioid pre-
scribing. 
‘‘(b) ELIGIBILITY.—To be eligible to receive a grant 
under subsection (a), a State must have in effect a law 
or regulation requiring covered health care providers, be-
fore issuing a new prescription for a covered drug or ana-
logue, to inform the patient involved, and the patient’s 
guardian if the patient has a guardian, about— 
‘‘(1) the risks of such covered drug or analogue; 
VerDate Sep 11 2014 
19:43 Mar 13, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1185.IH
H1185
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(2) the addictive qualities of such covered drug 
or analogue; and 
‘‘(3) non-opioid treatments to such covered 
drug or analogue, as appropriate. 
‘‘(c) GRANT AMOUNT.—The amount of a grant to a 
State under this section— 
‘‘(1) shall be greater than the amount of each 
grant to a State with a smaller number of covered 
health providers, as estimated by the Secretary; 
‘‘(2) shall not exceed $1,000,000; and 
‘‘(3) subject to the availability of funds, shall 
not be less than $750,000. 
‘‘(d) DEFINITIONS.—For purposes of this section: 
‘‘(1) COVERED
DRUG
OR
ANALOGUE.—The 
term ‘covered drug or analogue’ means a drug that 
is or contains an opioid (as defined in section 102 
of the Controlled Substances Act) or an analogue of 
an opioid. 
‘‘(2) COVERED HEALTH CARE PROVIDER.—The 
term ‘covered health care provider’ means a health 
care provider who issues prescriptions for a covered 
drug or analogue for the relief of acute pain. 
VerDate Sep 11 2014 
19:43 Mar 13, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1185.IH
H1185
pamtmann on DSKBC07HB2PROD with BILLS